13F Holdings
中文EN

CURX Curanex Pharmaceuticals Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 2025942 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-850.0%
TTM EPS YoY-509.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-146.5%
ROA-140.3%
ROIC (approx.)-207.7%
Asset turnover—

Leverage & solvency

Liabilities / assets17.8%
Debt / equity0.00x
Current ratio17.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.34x
Accruals ratio-91.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$2.99M—
SG&A expense$1.25M$290,386
Operating income-$4.24M-$365,062
Interest expense$8,537—
Net income-$4.23M-$361,506
EPS (basic)-0.17-0.03
EPS (diluted)-0.17-0.03
Weighted avg. shares (diluted)25.50M13.26M
Balance sheet
Cash & equivalents$4.97M$148,891
Current assets$11.23M$517,935
Total assets$11.58M$517,935
Current liabilities$137,030$14,575
Total liabilities$361,040$14,575
Shareholders' equity$11.22M$503,360
Shares outstanding1.42M1.20M
Cash flow statement
Operating cash flow-$10.48M-$555,575
Financing cash flow$15.31M$630,100

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.